<DOC>
	<DOCNO>NCT00625937</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , S-1 , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving one drug ( combination chemotherapy ) together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel S-1 together radiation therapy low-dose cisplatin work treat patient stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Docetaxel S-1 Followed By Radiation Therapy Low-Dose Cisplatin Treating Patients With Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess response rate patient stage III IV head neck cancer treat induction therapy comprise docetaxel S-1 follow radiotherapy low-dose cisplatin . Secondary - To assess effect regimen survival locoregional systemic control rate patient . OUTLINE : - Induction chemotherapy : Patients receive oral S-1 twice daily day 1-14 docetaxel IV 1 hour day 1 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . - Chemoradiotherapy : Patients receive low-dose cisplatin IV daily undergo radiotherapy 5 day week 7 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 18 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm head neck cancer arise oral cavity , oropharynx , hypopharynx , nasopharynx , include follow subtypes : Squamous cell carcinoma Poorly differentiate carcinoma Lymphoepithelioma Locally advance disease ( stage III IV [ M0 ] disease ) At least 1 unidimensionally measurable index lesion PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3.0 time ULN AST ALT ≤ 3.0 time ULN Creatinine ≤ 1.5 time ULN No concurrent serious systemic disorder , opinion investigator , would compromise patient 's ability complete study No serious cardiac condition , include follow : Myocardial infarction within past 6 month Angina NYHA class IIIIV heart disease No active infection require IV antibiotic , include active tuberculosis HIV No malignancy within past 5 year except basal cell carcinoma skin preinvasive carcinoma cervix Able comply protocol study procedure PRIOR CONCURRENT THERAPY : No prior radiotherapy chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>